FIELD: medicine; cardiology.
SUBSTANCE: therapeutically effective amount of pharmaceutical composition including chemical inhibitor of tyrosine kinase family Src. is introduced. Thus tyrosine kinase inhibitor is selected from group consisting of 4-4-5(4-methylphenyl)-7(tert-butyl)pyrazolo[3,4-d-]pyrimidine, 4-amino-5-(4-chlorophenyl)-7(tert-butyl)pyrazolo[3,4-d-]pyrimidine and their mixture.
EFFECT: reduction of vascular permeability and reduction of necrosis zone at myocardium infarction.
16 cl, 5 ex, 2 tbl, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MODULATORS OF ANGIOGENESIS AND VESSEL PERMEABILITY | 2000 |
|
RU2271216C2 |
| PYRIDINE DERIVATIVES AS INHIBITORS OF VASCULAR ENDOTHELIUM GROWTH FACTOR RECEPTORS 2 (VEGFR-2) AND PROTEIN TYROSINE KINASE | 2009 |
|
RU2522444C2 |
| METHOD OF TREATING OPHTHALMIC ANGIOGENESIS, RETINAL OEDEMA, RETINAL ISCHEMIA AND DIABETIC RETINOPATHY WITH USING SELECTIVE RTK INHIBITORS | 2006 |
|
RU2445096C2 |
| MODIFIED RNA ENCODING VEGF-A POLYPEPTIDES, COMPOSITIONS CONTAINING IT, AND THEIR APPLICATION METHODS | 2017 |
|
RU2756313C2 |
| METHODS OF TREATING OCULAR ANGIOGENESIS, RETINAL HYPOSTASIS, RETINAL ISCHEMIA AND DIABETIC RETINOPATHY WITH USING SELECTIVE RTK INHIBITORS | 2006 |
|
RU2396956C2 |
| USE OF PEPTIDE FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2013 |
|
RU2672341C2 |
| HUMAN PROTEIN TYROSINE PHOSPHATASE BETA BINDING ANTIBODIES (HPTPBETA), AND USE THEREOF | 2007 |
|
RU2494108C2 |
| HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND APPLICATION METHOD THEREOF | 2007 |
|
RU2430101C2 |
| PEPTIDES FOR INHIBITING ANGIOGENESIS | 2016 |
|
RU2708375C2 |
| COMPOUNDS | 2015 |
|
RU2690190C2 |
